A general platform for antibody purification utilizing engineered-micelles

Gunasekaran Dhandapania, Assaf Howardb, Thien Van Truonga, Thekke V. Baijuc, Ellina Kesselmana, Noga Friedmana, Ellen Wachteld, Mordechai Shevese, Dganit Daninon, Irishi N. N. Namboothirio, and Guy Patchornikb

aDepartment of Chemical Sciences, Ariel University, Ariel, Israel; bDepartment of Chemistry, Indian Institute of Technology Bombay, Powai, India; cFaculty of Biotechnology and Food Engineering, Technion, Haifa, Israel; dFaculty of Chemistry, Weizmann Institute of Science, Rehovot, Israel

ABSTRACT

We introduce a new concept and potentially general platform for antibody (Ab) purification that does not rely on chromatography or specific ligands (e.g., Protein A); rather, it makes use of detergent aggregates capable of efficiently capturing Ab while rejecting hydrophilic impurities. Captured Ab are then extracted from the aggregates in pure form without co-extraction of hydrophobic impurities or aggregate dissolution. The aggregates studied consist of conjugated “Engineered-micelles” built from the nonionic detergent, Tween-20; bathophenanthroline, a hydrophobic metal chelator, and Fe2+ ions. When tested in serum-free media with or without bovine serum albumin as additive, human or mouse IgGs were recovered with good overall yields (70–80%, by densitometry). Extraction of IgGs with 7 different buffers at pH 3.8 sheds light on possible interactions between captured Ab and their surrounding detergent matrix that lead to purity very similar to that obtained via Protein A or Protein G resins. Extracted Ab preserve their secondary structure, specificity and monomeric character as determined by circular dichroism, enzyme-linked immunosorbent assay and dynamic light scattering, respectively.

Introduction

Antibodies (Ab) are frequently encountered in scientific research as detection and quantitation agents and in medicine as vehicles for delivering drugs, enzymes and isotopes to target cells.1,2 Obtaining pure Ab preparations is obviously essential for these applications, and this is most commonly achieved by column chromatography with the ligand Protein A (ProA). ProA binds strongly3 and specifically4 to diverse Ab types, making it possible to efficiently capture Ab from complex media and reach high purity (>98%) within a single chromatographic step.5 Such remarkable features have made ProA chromatography the gold standard in Ab purification.6 Nevertheless, Ab purification without the need for ProA or chromatographic steps represents an appealing alternative, primarily due to: 1) the high cost of ProA resins and the potential leaching of ProA affinity columns which may pose a problem at high Ab concentrations;7 3) deamidation of ProA asparagines during column sanitation, leading to lower binding efficiency; and 4) the high maintenance costs associated with the use of high-performance liquid chromatography instrumentation. These experimental challenges have been the driving force behind the development of potentially more economical, non-chromatographic strategies for Ab purification. They include: 1) novel precipitation methods;9 2) aqueous two-phase extraction systems10,11 and 3) ultrafiltration with charged membranes.12 To the best of our knowledge, none of these approaches have been widely implemented.

Several publications demonstrating purification of diverse monoclonal Ab (mAb) by hydrophobic interaction chromatography (HIC)13 or hydrophobic membrane interaction chromatography14 are of particular relevance to the present study. These reports imply that mAb may have a tendency to bind more strongly to hydrophobic resins (or surfaces) compared to water-soluble proteins that are not immunoglobulins (IgGs). We therefore considered whether Ab would bind to detergent aggregates composed of conjugated Tween-20 micelles. Such aggregates are generated in a simple two-step sequence. First, the hydrophobic chelator, bathophenanthroline (batho), is added to a dispersion of Tween-20 micelles and transform the latter into what we have called ‘Engineered-micelles’.15–17 These contain, in addition to the detergent, a hydrophobic chelator that positions itself at the micelle/water interface (Figure 1). In the following step, Fe2+ ions are added as FeSO4. These ions serve as mediators between the engineered-micelles because they can bind with high affinity up to three batho molecules simultaneously,18 and, hence, lead to Tween-20 aggregates as a distinct hydrophobic phase (Figure 1).

We studied the potential of such hydrophobic aggregates to serve as a general purification platform for IgGs, regardless of the IgG origin. It was obvious that a practical IgG purification strategy would require a demonstration that Tween-20 aggregates: 1) bind IgGs efficiently; 2) exclude the majority of impurities; 3) allow IgG extraction from the aggregates without concomitant aggregate dissolution or co-extraction of hydrophobic impurities; and 4) lead to highly pure, monomeric and functional Ab molecules (Figure 1).
Figure 1. Illustration of antibody (Ab) purification using engineered-micelles. Non-ionic detergent micelles are transformed into engineered-micelles upon incubation with a hydrophobic chelator capable of positioning itself at the micelle-water interface. Specific conjugation of engineered-micelles is induced once Fe$^{2+}$ ions (FeSO$_4$) are added. Fe$^{2+}$ ions bind several chelators in parallel leading to detergent aggregates. Ab are captured by the detergent aggregates whereas more hydrophilic protein impurities, are rejected. Pure Ab are obtained by extraction from the aggregates without concomitant aggregate dissolution.
with these criteria is mandatory, highly challenging and represents the focus of our work.

Results

Preparation of conjugated Tween-20 micelles and their characterization by light microscopy and cryo-transmission electron microscopy

As described in the Material and Methods section, the preparation of Tween-20 aggregates requires only the addition of the chelator (batho) and Fe²⁺ ions to an aqueous medium containing Tween-20 micelles. These two additives trigger immediate formation of precipitates containing the red-colored, hydrophobic [(batho)₂;Fe²⁺] complex (Figure 2(a)). Following centrifugation (2 min., 14K), well-defined, red pellets and colorless supernatants are generated, indicating that most of the hydrophobic red complex had precipitated (Figure 2(a) – inset). Control experiments show that the presence of the chelator and the metal are both mandatory: in the absence of chelator, no aggregates, nor any form of phase separation, are observed, whereas in the absence of Fe²⁺, the chelator itself crystalizes as long, elongated rods (data not shown). To characterize the architecture of Tween-20 aggregates in more detail, cryo-transmission electron microscopy (cryo-TEM) was employed. Whereas cryo-TEM images of control samples, containing non-conjugated Tween-20 micelles, revealed a homogenous distribution of small micelles (Figure 2(b): white arrows), the aggregates appeared as a mixture of detergent clusters (Figure 2(c): white arrows) and elongated hydrophobic crystals. (Figure 2(c): blue arrows) These findings are consistent with our previous studies, and demonstrate the ability of the [(batho)₂;Fe²⁺] hydrophobic complex to conjugate non-ionic detergent micelles and to lead to condensed detergent aggregates.

Purification of human and mouse IgGs using Tween-20 aggregates

Our initial purification trials were aimed at assessing process viability and mandatory dependence on both the chelator (batho) and Fe²⁺ ions. As described in the Material and Methods section, a mixture of polyclonal human IgG (hlgG) and E. coli lysate (serving as an artificial contamination background) was added to preformed Tween-20 aggregates. A brief incubation (5 min.) was followed by centrifugation (2 min., 14K), the supernatant was discarded and the presence of the target IgG within the pellet was detected by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The heavy and light chains of the target IgG were clearly observed (Figure 2(d): lane 3) and provided direct evidence for Tween-20 aggregates’ ability to bind hlgG. Interestingly, the majority of bacterial proteins that were present in the system, together with the hlgG, were rejected from the aggregates (Figure 2(d): lane 1 vs. lane 3). Moreover, repetition of the same protocol in the absence of only the chelator (batho) (Figure 2(d): lane 4) or in the absence of only the Fe²⁺ (Figure 2(d): lane 5) led to a dramatic reduction in the intensity of the heavy and light chain bands of the target IgG in the aggregate. These results provided strong evidence for the participation and contribution of the hydrophobic chelator and metal ion (Fe²⁺) in the purification process. The appearance of a band at the front of lane 3 (see asterisk), was an unexpected finding since it did not appear in the contamination background (Figure 2(d): lane 1) nor in the target IgG (Figure 2, lane 2). This puzzle was solved when Tween-20 aggregates devoid of any protein (i.e., bacterial lysate or hlgG) were analyzed as well. This analysis showed that Tween-20 aggregates containing the [(batho)₂;Fe²⁺] hydrophobic complex (but not proteins) are stained by the Coomassie brilliant blue dye (R-250) and migrate to the front of the gel as observed (Figure 2, lane 6).

Purification of human and mouse IgGs in serum-free media

Process optimization trials in the presence of E. coli lysate were followed by implementation of the method in hybridoma serum-free media. Both hlgG and mouse IgG were detected by SDS-PAGE in the Tween-20 pellets (Figure 3(a) or (b): lane 2). Inclusion of bovine serum albumin (BSA) (or human serum albumin (HSA), data not shown) at concentrations higher than 0.5 mg/ml (in addition to the target IgG at 1 mg/mL), was found to progressively suppress IgG binding, concomitant with an increase of the albumin concentration within the aggregates (Figure 3(a) or (b): lanes 2–10). The finding that human and mouse IgGs can be extracted from Tween-20 aggregates with 50 mM isoleucine (pH 3.8) without significant co-extraction of BSA or aggregate dissolution, (Figure 3(c) or (d): lanes 3–4) was of particular importance. At higher BSA concentrations (≥0.5 mg/mL), albumin was observed along with the extracted IgG (Figure 3(a,b): lanes 5–10). Similar results were observed when BSA was replaced by HSA (data not shown).

Extraction buffers, circular dichroism and dynamic light scattering

The relative efficiency of extraction buffers (pH 3.8), containing different, individual amino acids, was studied. Highest overall yields of hlgG were obtained with Gly, Val or Ile buffers (Figure 3(e): lanes 3–5), while Arg or His buffers were found to be less efficient (Figure 3(e): lanes 6–7). The use of Asp or Glu buffers promoted partial aggregate dissolution, (Figure 3(e): lanes 8–9, viz., bands at the front of the gel). Incubation at 32 °C led to the highest extraction yields compared to lower temperatures (4–19 °C, data not shown); this was not of concern because therapeutic mAb were only reported to undergo chemical modification at higher temperatures (e.g., 37 °C, pH 4.5) and significantly longer incubation times (1–4 days). Implementation of the same extraction protocol on mouse IgGs showed that Gly or Ile buffers were the most efficient (Figure 3(f): lanes 3 and 5); His buffer was moderately efficient (Figure 5(e): lane 7); and Val or Arg buffers were inefficient (Figure 3(f): lanes 4 and 6). The tendency of Asp or Glu buffers to dissolve Tween-20 aggregates was again observed (Figure 3(f): lanes 8–9).
Comparison of the circular dichroism (CD) spectrum of hIgGs that were subjected to purification with Tween-20 aggregates and extracted in Gly buffer with that of untreated, control hIgGs, showed that the spectra are very similar. Both reveal the prominent secondary structure of IgGs (i.e., anti-parallel beta-sheets) with strong negative ellipticity band at 218 nm, and are in agreement with previous reports in the literature (Figure 4(a)). Since similar spectra were also obtained with mouse IgGs (Figure 4(b)), we conclude that micelle-based purification is mild and is capable of preserving IgGs secondary structure.

Dynamic light scattering (DLS) measurements did not demonstrate any significant differences in the size distribution of purified hIgG or mouse IgG extracted with each of three buffers (50 mM Gly, Ile or His, pH 3.8) from untreated, control IgGs (Figure 4(c,d)). No evidence for IgG aggregates was observed. Still, a slight increase in size (~10%) of the purified IgGs was detected, which may represent bound Tween-20 detergent monomers (Figure 4(c,d)).

**Preservation of IgG specificity**

Preservation of IgG specificity upon completion of the purification process was studied with two types of polyclonal antibodies (sheep and rabbit) that recognize BSA. Each of these Ab was purified with Tween-20 aggregates (containing only HSA in order to eliminate BSA from the system); extracted with each of the 7 buffers studied; and finally, tested for their ability to bind target BSA in an enzyme-linked immunosorbent assay (ELISA). Differences in the ELISA signals observed (Figure 4(e,f)) reflect differences in extraction efficiency as had been observed with hIgG and mouse IgG (Figure 3(e,f)). The strongest signals were obtained when extraction buffers were composed of Asp or Glu. These findings are consistent with those described earlier, where it was shown that Asp and Glu buffers induce partial aggregate dissolution (Figure 3(e,f)); lanes 8–9) and lead to higher IgG concentration in the extraction buffer (i.e., supernatant) (Figure 4(e,f)).
Discussion

The development of a non-chromatographic platform for Ab purification, one not requiring the use of the gold standard ligand, ProA, has proven to be a true challenge. However, an alternative approach seemed possible when detergent aggregates comprising Tween-20 and the hydrophobic [(batho)₃Fe²⁺] red complex demonstrated an ability to specifically capture human IgG, while excluding the large majority of impurities present in an E. coli lysate included as an artificial background. We observed similar efficiency in hybridoma serum-free media, i.e., the common environment for mAb production. Interestingly, inclusion of BSA, an albumin that contributes to the successful culture of mammalian cells and to stimulation of hybridoma cell growth, showed that it competes with IgGs for binding to the Tween-20 aggregates. However, when equimolar amounts of target IgGs and BSA were present, IgG capturing efficiency was not affected and remained quantitative (by densitometry). Consistent with the above, analysis of the supernatant after IgG capture confirmed that no IgG (human or mouse) are present in the supernatant when the molar concentration of BSA is not higher than that of the IgG (Supplementary, S1: A and B lanes 4–5). Under these conditions, analysis of the pellet under non-reducing conditions, also showed that only the pellets contained intact IgGs, but not the supernatant (Supplementary, S1: C lanes 3–4 for hlgG; lanes 8–9 for mouse IgG).

Figure 3. IgG purification in serum-free media with or without added BSA. IgG capture: (a). Human IgG (hlgG) capture: Lane 1: hlgG and BSA; lanes 2–10: Pellet composition obtained after incubating Tween-20 aggregates with hlgG (1 mg/mL) and the indicated BSA concentrations in serum-free media as described in Experimental. (b). Gel B, as described in A, but with mouse IgG rather than human. (c-d). Supernatant composition after incubating the pellets with 50 mM isoleucine at pH 3.8 as described in Experimental. (e). Effect of buffer composition on IgG extraction. Lane 1: hlgG and BSA; lane 2: Pellet composition obtained after incubating Tween-20 aggregates with hlgG (1 mg/mL) and BSA (0.5 mg/mL) in serum free-media as described in Experimental; lanes 3–9: Supernatant composition after extracting hlgG from pellets generated under conditions shown in lane 2 with buffers containing the amino acids indicated at pH 3.8 as described in Experimental. (f). As in E, but in the presence of mouse IgG. H, L denote the reduced heavy and light chains of the target antibody, respectively. A points to the detergent aggregate band. Gels are stained with Coomassie blue.
Figure 4. (a-b) CD spectra. Human and mouse IgGs were subjected to purification with Tween-20 aggregates and extracted with Gly buffer at pH 3.8. CD spectra of control IgGs (i.e., untreated IgGs – solid line) and IgGs that were subjected to purification (dotted line) are shown. (c-d) Dynamic light scattering (DLS). Human and mouse IgGs were purified as described in A-B and extracted with indicated buffers at pH 3.8. Control untreated IgGs – solid line, purified IgGs – dotted line. (e-f) ELISA analysis of extracted IgGs. Polyclonal anti-BSA IgGs originating from rabbit (naked) or sheep (biotinylated) were subjected to the micelle-based purification method and extracted at 32 °C (5 min.) from Tween-20 aggregates with the amino acid buffers indicated (50 mM) at pH 3.8. The ability of the purified Ab to bind target epitopes on BSA was determined by ELISA assays as described in the Material and Methods section. The data presented are the results of at least 12 independent experiments.
IgG purity was achieved by defining conditions under which captured IgGs were extracted from the Tween-20 aggregates without concomitant pellet dissociation or co-extraction of hydrophobic impurities. Notably, low salt concentration (30 mM NaCl) was required in order to prevent pellet dissolution. Extraction was performed at pH 3.8 to avoid co-extraction of BSA, which occurs under more acidic conditions.\textsuperscript{26,27} To characterize the interactions between captured IgGs and their detergent surroundings, seven different buffers, each containing 50 mM of individual amino acids, potential competitors for IgG side chain interactions, were studied to access: 1) hydrophobic interactions (Val, Ile); 2) ionic and H-bond interactions (Asp, Glu, Arg); or 3) metal chelation (His). These buffers were compared to the Gly buffer, commonly used for IgG elution from ProA columns.\textsuperscript{28} For IgG, the most efficient extraction buffers were Gly, Val or Ile, suggesting that IgGs may be involved in van der Waals interactions with the surrounding detergent matrix. By contrast, partial aggregate dissolution was observed when Asp or Glu buffers were used. That it was in fact possible to define conditions under which albumin molecules (BSA, HSA) do not elute together with the IgGs, suggested that this tighter binding may derive from interaction between high affinity metal binding sites of albumins\textsuperscript{27–29} and bound Fe\textsuperscript{2+} ions embedded in the detergent matrix. Repetition of the above buffer survey with mouse IgGs led to a similar but not identical extraction profile.

IgGs subjected to the Tween-20 micelle-based purification process preserve their secondary structure: anti-parallel beta-sheets and the characteristic ellipticity band at \( \approx 218 \) nm are both clearly observed in CD spectra. Additional measurements in the near UV (260–380 nm) showed that the tertiary structure of both human and mouse IgGs is also preserved (Supplementary, S1: D and E). This stability may derive from interaction between high affinity metal binding sites of albumins\textsuperscript{27–29} and bound Fe\textsuperscript{2+} ions embedded in the detergent matrix. Repetition of the above buffer survey with mouse IgGs led to a similar but not identical extraction profile.

IgGs subjected to the Tween-20 micelle-based purification process preserve their secondary structure: anti-parallel beta-sheets and the characteristic ellipticity band at \( \approx 218 \) nm are both clearly observed in CD spectra. Additional measurements in the near UV (260–380 nm) showed that the tertiary structure of both human and mouse IgGs is also preserved (Supplementary, S1: D and E). This stability may derive from interaction between high affinity metal binding sites of albumins\textsuperscript{27–29} and bound Fe\textsuperscript{2+} ions embedded in the detergent matrix. Repetition of the above buffer survey with mouse IgGs led to a similar but not identical extraction profile.
Preparation of Tween-20 aggregates (Tween-20: bathophenanthroline: Fe⁷⁺)

Tween-20 aggregates were obtained by mixing equal volumes of medium A and B as follows: medium A was prepared by the addition of 30 μL of the hydrophobic chelator bathophenanthroline (20 mM in methanol) to 270 μL of 0.25 mM Tween-20 in DDW with vigorous vortexing to a final volume of 300 μL. An equal volume of medium B, containing 1 mM FeSO⁴ in 20 mM NaCl was then added to medium A with vigorous vortexing.

Purification of hIgG and mouse IgG with Tween-20 aggregates

Freshly prepared Tween-20 aggregates were resuspended in 100 μL serum-free medium (Ex-CELL 610-HSF) containing: 5% PEG-6000, the target IgG (1 mg/mL) and BSA or HSA (0 – 10 mg/mL). After 5 – 10 minutes incubation at room temperature, centrifugation (14K, 2 min.) was applied, the supernatant discarded, and pellets were briefly washed with 100 μL of cold 20 mM NaCl. An additional centrifugation step followed (14K rpm, 2 min.), the supernatant was removed, and pellets were analyzed by SDS-PAGE. Similarly, human and mouse IgGs were purified from E. coli lysate in the presence of vigorous vortexing.

Extraction of IgGs from Tween-20 aggregates

Tween-20 pellets containing target IgG were incubated with 100 μL of either: 50 mM Gly, Val, Ile, Arg, His, Asp or Glu (pH 3.8), 30 mM NaCl for 5 minutes at 32 °C. Centrifugation followed (13K rpm, 2 min.) and the supernatant was carefully removed for further analysis.

Comparison study against ProA and Protein G spin columns

The IgG:BSA sample, prepared as described above, was applied to commercial ProA or Protein G spin columns and purification was performed according to manufacturer instructions (General Electric). Eluted IgGs were then compared to those purified using Tween-20 aggregates.

Cryo-TEM analysis

Tween-20 aggregates were prepared as described above and aliquots (10 μL) were used for cryo-TEM analysis. Samples were prepared in a controlled environment vitrification system (CEVS),¹⁹,³³ equilibrated at 25 °C and at saturation. Vitrified specimens were examined in an FEI T12 G² TEM operating at 120 kV. Images were recorded under low dose conditions as described previously.¹⁹,³³

Dynamic light scattering

IgG (0.5 – 1.0 mg/mL), treated and untreated, was solubilized in one of three buffers: 50 mM glycine + 30 mM NaCl, pH 3.8: 50 mM isoleucine + 30 mM NaCl, pH 3.8; and 50 mM histidine + 30 mM NaCl pH 3.8. Samples were centrifuged at 13,000 rpm for 20 min and the supernatant collected for analysis. The intensity-weighted size distributions of human and mouse IgG samples were determined using the auto correlation spectroscopy protocol of the Nanophox instrument (Sympatec GmbH, Germany).

Circular dichroism spectroscopy

Antibodies that were extracted from Tween-20 aggregates as described above were subjected to CD analysis using...
a Chirascan CD spectrometer (Applied Photophysics). CD spectra report ellipticity (θ), proportional to the difference in absorbance of left and right circularly polarized light [θ = 3300°] (AL–AR) as a function of wavelength. A quartz cell with dimensions 10 × 10 mm; light path of 10 mm, was used. The CD spectra were recorded with 1 nm bandwidth resolution in 1 nm steps at 20°C. The CD spectra were corrected for baseline distortion by subtracting a reference spectrum of the corresponding buffer.

**Enzyme-linked immunosorbent assay**

Nunc-Immuno Microwell plates (F96 Maxisorp) were first coated with 2% BSA (200 µL), left for overnight incubation at 4 °C, and excess of BSA was removed with three aliquots of PBS (200 µL). Purified anti-BSA IgGs, i.e., IgGs that had been captured by Tween-20 aggregates and extracted with amino acid buffer, were then added to the washed wells. Accordingly, 100 µL of purified and diluted (1:250) biotinylated anti-BSA IgG (sheep) or diluted (1:1200) naked anti-BSA IgG (rabbit) were added to the BSA coated wells, incubated for 2 hours at room temperature (RT) and unbound anti-BSA IgGs were then removed with PBS (3 x 200 µL). To wells containing the biotinylated anti-BSA IgG, a diluted (1:200) streptavidin-HRP conjugate was added (100 µL), whereas a diluted (1:15,000) anti-rabbit IgG-HRP conjugate was introduced into wells containing the naked IgG. In both cases, the system was further incubated for 1 hour at RT and excess HRP-conjugates (either streptavidin or IgG) were excluded with PBS (3 x 200 µL). Addition of the HRP substrate (1XTMB solution) was followed by 10 minutes of incubation at RT and the reaction was stopped upon addition of 2 N HSO₄ (50 µL). The intensity of the yellow color in the wells was measured at 450 nm using an ELISA reader (Tecan infinite M200).

**Densitometry**

Bands present in Coomassie-stained gels were quantified using the EZQuant program. [http://www.ezquant.com/en/](http://www.ezquant.com/en/)

**Light microscopy**

Images were obtained using an Olympus CX-40 light microscope equipped with an Olympus U-TV1X-2 digital camera.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| Ab           | Antibody    |
| Arg          | Arginine    |
| Asp          | Aspartic acid |
| Batho        | Bathophenanthroline |
| BSA          | Bovine serum albumin |
| CD           | Circular dichroism |
| Cryo-TEM     | Cryo-transmission electron microscopy |
| DLS          | Dynamic light scattering |
| E. coli      | Escherichia coli |
| ELISA        | Enzyme-linked immunosorbent assay |
| Glu          | Glutamic acid |
| Gly          | Glycine     |
| His          | Histidine   |
| hIgG         | Human IgG   |
| HPLC         | High-performance liquid chromatography |
| HSA          | Human serum albumin |
| IgA          | Immunoglobulin A |
| IgG          | Immunoglobulin G |
| IgM          | Immunoglobulin M |
| Ile          | Isoleucine  |
| mAb          | Monoclonal antibody |
| ProA         | Protein A   |
| SDS-PAGE     | Sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| Tween-20     | Polysorbate 20 |
| UV           | Ultraviolet |
| Val          | Valine      |

**Acknowledgments**

We thank the Kimmelman Center for Biomolecular Structure and Assembly at the Weizmann Institute of Science for its generous support (to M.S.). M. S. holds the Katzir-Makineni chair in chemistry. D. D. thanks the Israel Science Foundation and the Russell Berrie Nanotechnology Institute, Technion for their support. G. P. thanks Prof. M. Firer for the use of the ELISA reader and Ariel University for their support.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**ORCID**

Mordechai Sheves [http://orcid.org/0000-0002-5048-8169](http://orcid.org/0000-0002-5048-8169)

Irishi N. N. Namboothiri [http://orcid.org/0000-0002-8945-3932](http://orcid.org/0000-0002-8945-3932)

Guy Patchornik [http://orcid.org/0000-0002-6472-8354](http://orcid.org/0000-0002-6472-8354)

**References**

1. Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol. 2004;4(2):153–56. doi:10.1038/nri1265.
2. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–70. doi:10.1038/nrc3930.
3. Hober S, Nord K, Linhult M. Protein A chromatography for antibody purification. J Chromatogr B. 2007;848(1):40–47. doi:10.1016/j.jchromb.2006.09.030.
4. DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent solutions to binding at a protein-protein interface. Science. 2000;287:1279–83.
5. Azvedo AM, Gomes AG, Rosa PAJ, Ferreira IF, Picco AMMO, Aires-Barros MR. Partitioning of human antibodies in polyethylene glycol–sodium citrate aqueous two-phase systems. Sep Purif Technol. 2009;65(1):14–21. doi:10.1016/j.seppur.2007.12.010.
6. Low D, O’Leary R, Pujar NS. Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848(1):48–63. doi:10.1016/j.jchromb.2006.10.033.
7. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22(11):1393–98. doi:10.1038/nbt1026.
8. Linhult M, Gulich S, Graslund T, Simon A, Karlsson M, Sjoberg A, Nord K, Hober S. Improving the tolerance of a protein analogue to repeated alkaline exposures using a bypass mutagenesis approach. Proteins. 2004;55(2):407–16. doi:10.1002/prot.10616.
9. McDonal P, Victa C, Carter-Franklin JN, Fahrner R. Selective antibody precipitation using polyelectrolytes: a novel approach to the purification of monoclonal antibodies. Biotechnol Bioeng. 2009;102(4):1141–51. doi:10.1002/bit.22127.
10. Azvedo AM, Rosa PA, Ferreira IF, Aires-Barros MR. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. Trends Biotechnol. 2009;27(4):240–47. doi:10.1016/j.tibtech.2009.01.004.
11. Mao LN, Rogers JK, Westoby M, Conley L, Pieracci J. Downstream antibody purification using aqueous two-phase extraction. Biotechnol Prog. 2010;26(6):1662–70. doi:10.1002/btpr.477.
12. van Rees R, Zydney A. Bioprocess membrane technology. J Membr Sci. 2007;297(1–2):16–50. doi:10.1016/j.memsci.2007.02.045.
13. Manzke O, Tesch H, Diehl V, Bohlen H. Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J Immunol Methods. 1997;208:65–73.
14. Ghosh R, Wang L. Purification of humanized monoclonal antibody by hydrophobic interaction membrane chromatography. J Chromatogr A. 2006;1107(1):104–9. doi:10.1016/j.chroma.2005.12.035.
15. Patchornik G, Namboothiri INN, Nair DK, Wachtel E, Persky R. Tethered non-ionic micelles: a matrix for enhanced solubilization of lipophilic compounds. Soft Matter. 2012;8(32):8456–63. doi:10.1039/c2sm25708d.
16. Patchornik G, Wachtel E, Kesselman E, Danino D. Cryo-TEM structural analysis of conjugated nonionic engineered-micelles. Soft Matter. 2014;10(27):4922–28. doi:10.1039/c4sm00462k.
17. Dutta S, Nair DK, Namboothiri IN, Wachtel E, Friedman N, Sheves M, Patchornik G. Engineered-membranes and engineered-micelles as efficient tools for purification of halorhopasin and bacteriorhodopsin. Analyst. 2015;140(1):204–12. doi:10.1039/c4an01423e.
18. Martell AE, Smith RM. Critical stability constants. New York (NY): Plenum Press; 1974.
19. Danino D. Cryo-TEM of soft molecular assemblies. Curr Opin Colloid Interface Sci. 2012;17(6):316–29. doi:10.1016/j.cocis.2012.10.003.
20. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109(40):16101–06. doi:10.1073/pnas.1211023109.
21. Padlan EA. Anatomy of the antibody molecule. Mol Immunol. 1994;31:169–217.
22. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2006;1(6):2876–90. doi:10.1038/nprot.2006.202.
23. Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T. Characterization of protein aggregation: the case of a therapeutic immunoglobulin. Biochim Biophys Acta. 2007;1774(1):146–53. doi:10.1016/j.bbapap.2006.10.010.
24. Francis GL. Albumin and mammalian cell culture: implications for biotechnology applications. Cytotechnology. 2010;62(1):1–16. doi:10.1007/s10616-010-9263-3.
25. Glassy MC, Tharakar JP, Chau PC. Serum-free media in hybridoma culture and monoclonal antibody production. Biotechnol Bioeng. 1988;32(8):1015–28. doi:10.1002/bit.260320809.
26. Narhi LO, Caughey DJ, Horan T, Kita Y, Chang D, Arakawa T. Effect of three elution buffers on the recovery and structure of monoclonal antibodies. Anal Biochem. 1997;253(2):236–45. doi:10.1006/abio.1997.2375.
27. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem. 1994;45:153–203.
28. Rozga M, Sokolowska M, Protas AM, Bal W. Human serum albumin coordinates Cu(II) at its N-terminal binding site with 1 pM affinity. J Bio Inorg Chem. 2007;12(6):913–18. doi:10.1007/s00775-007-0244-8.
29. Bourdon E, Loreau N, Lagrost L, Blache D. Differential effects of cysteine and methionine residues in the antioxidant activity of human serum albumin. Free Radic Res. 2005;39:15–20. doi:10.1080/10715760400024935.
30. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. mAbs. 2012;4(1):17–23. doi:10.4161/mabs.4.1.18347.
31. Roberts CJ. Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol. 2014;32(7):372–80. doi:10.1016/j.tibtech.2014.05.005.
32. Pollman DK, Fahrner RL. Factorial screening of antibody purification processes using three chromatography steps without protein A. J Chromatogr A. 2004;1024:79–85. doi:10.1016/j.chroma.2003.10.060.
33. Danino D, Bernheim-Groswasser A, Talmon Y. Digital cryogenic transmission electron microscopy: an advanced tool for direct imaging of complex fluids. Colloids Surf A. 2001;183-185:113–22. doi:10.1016/S0927-7757(01)00543-X.